HomeCompareRVLP vs QYLD

RVLP vs QYLD: Dividend Comparison 2026

RVLP yields 7092.20% · QYLD yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVLP wins by $1884093739015635.50M in total portfolio value
10 years
RVLP
RVLP
● Live price
7092.20%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1884093739015635.50M
Annual income
$1,833,245,317,704,596,000,000.00
Full RVLP calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.85%
Share price
$17.25
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.2K
Annual income
$5,580.19
Full QYLD calculator →

Portfolio growth — RVLP vs QYLD

📍 RVLP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVLPQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVLP + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVLP pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVLP
Annual income on $10K today (after 15% tax)
$602,836.88/yr
After 10yr DRIP, annual income (after tax)
$1,558,258,520,048,906,500,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,007.63/yr
After 10yr DRIP, annual income (after tax)
$4,743.16/yr
At 15% tax rate, RVLP beats the other by $1,558,258,520,048,906,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVLP + QYLD for your $10,000?

RVLP: 50%QYLD: 50%
100% QYLD50/50100% RVLP
Portfolio after 10yr
$942046869507817.75M
Annual income
$916,622,658,852,298,000,000.00/yr
Blended yield
97.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RVLP right now

RVLP
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
-11.5
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVLP buys
0
QYLD buys
0
No recent congressional trades found for RVLP or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVLPQYLD
Forward yield7092.20%11.85%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1884093739015635.50M$25.2K
Annual income after 10y$1,833,245,317,704,596,000,000.00$5,580.19
Total dividends collected$1880686879940887.75M$26.8K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: RVLP vs QYLD ($10,000, DRIP)

YearRVLP PortfolioRVLP Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$719,920$709,219.86$10,345$1,185.45+$709.6KRVLP
2$48,488,208$47,717,893.43$10,815$1,338.87+$48.48MRVLP
3$3,055,533,336$3,003,650,953.86$11,435$1,528.03+$3055.52MRVLP
4$180,164,837,337$176,895,416,667.11$12,238$1,763.71+$180164.83MRVLP
5$9,940,782,885,418$9,748,006,509,468.02$13,271$2,060.69+$9940782.87MRVLP
6$513,306,198,719,386$502,669,561,031,988.20$14,595$2,439.49+$513306198.70MRVLP
7$24,807,223,019,401,092$24,257,985,386,771,350.00$16,299$2,929.06+$24807223019.38MRVLP
8$1,122,195,624,531,859,500$1,095,651,895,901,100,200.00$18,500$3,570.77+$1122195624531.84MRVLP
9$47,521,889,075,737,830,000$46,321,139,757,488,740,000.00$21,371$4,424.82+$47521889075737.80MRVLP
10$1,884,093,739,015,635,500,000$1,833,245,317,704,596,000,000.00$25,156$5,580.19+$1884093739015635.50MRVLP

RVLP vs QYLD: Complete Analysis 2026

RVLPStock

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Full RVLP Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this RVLP vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVLP vs SCHDRVLP vs JEPIRVLP vs ORVLP vs KORVLP vs MAINRVLP vs XYLDRVLP vs JEPQRVLP vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.